Buch, Englisch, Format (B × H): 178 mm x 254 mm, Gewicht: 430 g
Buch, Englisch, Format (B × H): 178 mm x 254 mm, Gewicht: 430 g
ISBN: 978-0-443-12143-2
Verlag: Churchill Livingstone
In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more. - Contains 17 relevant, practice-oriented topics including the changing epidemiology of cardiac amyloidosis; arrhythmic stratification of cardiac amyloidosis: state of the art; specific therapy in ATTR-related cardiomyopathy: future perspectives beyond tafamidis; and more.
- Provides in-depth clinical reviews on amyloid cardiomyopathies, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Amyloidosis and Amyloidogenesis: One Name, Many Diseases
Pathophysiology of Cardiac Amyloidosis
The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis
Clinical Use of Biomarkers in Cardiac Amyloidosis
Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis
Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update
Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray”
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis
